Strategic Liability Management: Runway Growth Taps Retail Bonds to Retire Debt

MENLO PARK, Calif. – September 23, 2026 — In a macroeconomic environment where the cost of capital dictates the survival and prosperity of non-bank lenders, balance sheet optimization is no longer a luxury—it is an operational imperative. Runway Growth Finance Corp. (Nasdaq: RWAY), a prominent specialty finance company providing flexible capital to late- and growth-stage companies, announced today the commencement of an underwritten public offering of unsecured notes. Subject to market conditions, the new notes are expected to be listed on the Nasdaq Global Select Market, trading within 30 days of their original issue date.

While the issuance of corporate debt is routine, the underlying mechanics of this specific transaction reveal a highly calculated defensive maneuver. The primary objective of the offering is to redeem all or a portion of the company’s outstanding 9.00% Senior Notes due January 31, 2027. These notes, of which approximately $33.0 million remain outstanding, represent the single most expensive fixed-rate debt tranche in Runway’s capital structure.

By tapping the exchange-traded debt markets—often referred to as the "baby bond" market—Runway Growth is executing a textbook liability management exercise. It is simultaneously extending its debt maturity profile, defending its net investment income margins, and navigating a shifting venture lending landscape that demands robust liquidity.

The Economics of the Trade: Cutting Loose 9% Debt

To understand the significance of today's offering, one must look back to April 2026, when Runway Growth completed its transformative $249.0 million acquisition of SWK Holdings Corporation. Along with a lucrative portfolio of healthcare and life sciences assets, Runway inherited SWK's liabilities, assuming the 9.00% Senior Notes through a supplemental indenture.

In the current fixed-income climate, a 9.00% coupon is an anchor on profitability. Runway’s recent debt issuances establish a more favorable benchmark pricing range of 7.00% to 7.25%, evidenced by its February 2026 issuance of 7.25% Notes due 2031 (Nasdaq: RWAYI) and May 2026 issuance of 7.00% Notes due 2029.

Replacing legacy merger paper with newly minted notes at a lower coupon is a direct injection to the bottom line. If the underwriters price this new 2031 paper at 7.25%, the company is instantly shaving 175 basis points off that $33.0 million liability. That equates to over half a million dollars in annual interest savings.

For a Business Development Company (BDC), where dividend coverage is the ultimate metric of success, every basis point matters. In the second quarter of 2026, Runway reported Net Investment Income (NII) of $18.2 million, or $0.43 per share, comfortably covering its regular dividend of $0.33 per share. By reducing interest expenses, management is actively insulating that dividend coverage ratio against future fluctuations in base interest rates or potential portfolio credit turbulence. Furthermore, extending the maturity of this debt from early 2027 to 2031 removes a near-term refinancing cliff, providing the firm with over four years of operational runway to deploy capital without the pressure of an impending debt maturity.

Excess proceeds from the offering are earmarked for general corporate purposes, which likely includes paying down the firm's KeyBank credit facility. With the revolver floating at Adjusted Term SOFR plus a spread, carrying effective rates near 8.0%, paying down this facility frees up revolving borrowing capacity to meet the company's $146.7 million in unfunded loan commitments.

Shifting Portfolios: From Venture Tech to Life Sciences

The backdrop to this debt offering is a broader evolution in Runway Growth’s portfolio strategy, reflecting the complex realities of the modern venture capital ecosystem. For years, non-bank venture lenders feasted on the explosive growth of late-stage technology startups. However, the subsequent valuation resets and a higher-for-longer interest rate environment have exposed vulnerabilities in tech-heavy portfolios.

Runway has not been immune to these macroeconomic forces. Data from the company's second-quarter filings revealed that non-accruals accounted for 3.78% of portfolio fair value as of June 30, 2026. Credit stress has been heavily concentrated in a few high-profile restructurings, notably Marley Spoon SE and Blueshift Labs, Inc., which drove a $45.3 million net realized loss in the second quarter.

Recognizing the volatility inherent in technology venture lending, Runway's leadership—including Founder and Co-CEO David Spreng—pivoted decisively toward more resilient sectors. The acquisition of SWK Holdings was the catalyst, expanding Runway's healthcare and life sciences exposure from a modest 14% to approximately 32% of total investments. Healthcare royalty loans and life science debt typically offer more predictable cash flows, insulated from the consumer discretionary pullbacks and enterprise software spending cuts that have plagued traditional tech borrowers.

This strategic pivot underscores the defensive nature of today's note offering. By securing long-term, fixed-rate capital, Runway is fortifying a $1.2 billion portfolio that is increasingly anchored by the stability of the global healthcare sector. The firm's dollar-weighted annualized debt yield stood at an impressive 14.2% in the second quarter, largely supported by a portfolio composed of 95.7% first-lien senior secured debt.

The Retail Bond Alternative in a Discounted Equity Market

For investors, the new unsecured notes present a fascinating alternative to Runway Growth's common equity. The BDC sector has experienced a stark bifurcation in 2026. While underlying net investment income remains robust, equity markets have heavily discounted the common shares of venture-focused lenders due to fears of further unrealized losses and Net Asset Value (NAV) degradation.

Runway Growth's common equity is a prime example of this disconnect. Despite reporting a NAV of $11.91 per share at the end of the second quarter, the company's stock has languished near the $6.50 to $6.75 range—a staggering discount of approximately 44%. This massive valuation gap prompted management to authorize a $15.0 million common share repurchase program in May, followed by a wave of insider buying in August and September. Co-CEO Michael Rovner, CFO Carmela Thomson, and Director Edward J. Goldthorpe all executed significant open-market purchases of common stock, signaling deep internal conviction in the firm's underlying asset quality.

However, for income-focused retail and institutional investors wary of equity market volatility, the newly announced exchange-traded notes offer a highly compelling proposition. Structured in $25 par value denominations—the hallmark of the retail bond market—these securities provide accessible, senior-ranking exposure to Runway's cash flows.

Historically, Runway's exchange-traded senior unsecured debt has held an investment-grade rating of BBB+ from Egan-Jones Rating Company. Under the Investment Company Act of 1940, BDCs are required to maintain a statutory asset coverage ratio of at least 150% for senior debt, providing bondholders with a substantial structural cushion against portfolio losses.

The joint book-running syndicate for the offering—comprising Oppenheimer & Co. Inc., B. Riley Securities, Inc., Lucid Capital Markets, LLC, and MUFG Securities Americas Inc.—is targeting a fixed-income investor base that prioritizes capital preservation over capital appreciation. Co-managed by Compass Point Research & Trading, Ladenburg Thalmann, InspereX, William Blair, and BC Partners Securities, the distribution network is engineered to reach retail brokerage accounts where yield-hungry investors reside.

While the final interest rate and terms will be determined at pricing, peer comparisons suggest a yield in the low-to-mid 7% range. Against the backdrop of Runway's common stock, which currently sports a theoretically massive dividend yield due to its depressed share price, the baby bonds offer a sanctuary. They rank equal in right of payment to all existing unsecured debt and hold strict priority over common equity dividends.

In dissecting this transaction, it becomes clear that Runway Growth Finance is executing a multifaceted strategy. It is not merely raising capital; it is actively managing its liabilities, optimizing its cost structure, and tailoring its financial instruments to meet the bifurcated demands of the modern capital markets. By cleanly excising its 9.00% legacy debt, the firm is positioning its balance sheet to weather the lingering uncertainties of the venture capital ecosystem while capitalizing on its newly acquired strength in the life sciences sector.